EvoEnzyme is a spin-off from CSIC, Spain, which focuses its activities on the commercialization of ligninolytic enzymes engineered by directed evolution for the pharma and industrial sectors, together with the development of directed evolution projects. EvoEnzyme has just been funded after over 15 years of research at the Miguel Alcalde group, whose more relevant findings have been transferred to the company. With an ensemble of top-notch technologies, EvoEnzyme offers a variety of methods for library creation and screening aimed at designing customized biocatalysts. The company has a wide portfolio of mutant libraries, including peroxygenases for the pharma industry and chemicals as well as laccases and peroxidases for the long-pursued lignocellulose biorefineries.